Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Frontera London

- PMLiVE

NICE recommends Immunocore’s Kimmtrak as first drug for aggressive eye cancer

More than 100 patients are expected to be eligible for the treatment every year

- PMLiVE

Best practices for conquering data management challenges in the pharma industry

The importance of protecting pharma data that can be highly sensitive and subject to data privacy regulations

Ispor Europe poster winning authors

Genesis Research Group’s ISPOR Europe award-winning poster authors interviewed online

Genesis Research Group's poster 'Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey' was recently named as...

Genesis Research Group

- PMLiVE

Novartis gains rights to PTC’s Huntington’s programme in deal worth up to $2.9bn

The genetic disorder affects one in every 10,000 to 20,000 people in the US

- PMLiVE

Amgen’s investigational weight-loss drug MariTide shows promise in mid-stage study

The company has announced a phase 3 programme across obesity and related conditions

- PMLiVE

Bridging gaps and breaking barriers in pharma alliances

The future of healthcare will be forged on collaboration

- PMLiVE

FAQs about systematic literature reviews and network meta-analyses in healthcare

Are you new to the world of evidence synthesis for market access? Are you unsure about some of the terminology used by specialists who are preparing your evidence dossier? Here,...

Petauri Evidence

- PMLiVE

Highlighting the Power of Patient-Integration

Advancing person-centered care is an important topic for the Medscape Oncology team, and no one knows this better than Dr Victoria Harvey-Jones, Associate Director of Clinical Strategy for Medscape Oncology...

Medscape Education

- PMLiVE

MHRA urges companies to prepare for Windsor Framework for medicines

The new UK-wide arrangements for medicines will come into effect on 1 January 2025

- PMLiVE

Merck shares positive phase 3 results for pulmonary arterial hypertension therapy

The progressive blood vessel disorder affects approximately 40,000 people in the US

- PMLiVE

Enabling a sustainable and mutually beneficial CDMO partnership

There are a multitude of CDMO options available, all providing specialised expertise and solutions for diverse and complex activities

- PMLiVE

UK researchers uncover first new asthma and COPD attack treatment in 50 years

The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links